These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 7493132)

  • 41. [Value of irradiation of the base of the orbit in patients with malignant exophthalmia. Experience of the Jules Bordet Institute 1974-1983].
    Regnier R; Conreur L; Schrooyen M; Glinoer D; Lemort M; Massant B
    Rev Med Brux; 1986 Sep; 7(7):419-25. PubMed ID: 2429357
    [No Abstract]   [Full Text] [Related]  

  • 42. Management of progressive exophthalmos.
    Kumar S; Subhankar C; Sen SC
    Indian J Ophthalmol; 1990; 38(2):61-3. PubMed ID: 2387602
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The problem of optimal radioiodine therapy in Basedow's disease].
    Fazakas S
    Acta Med Acad Sci Hung; 1969; 26(1):31-40. PubMed ID: 5819409
    [No Abstract]   [Full Text] [Related]  

  • 44. Corticosteroids in the treatment of optic nerve involvement associated with thyroid dysfunction.
    Day RM; Carroll FD
    Arch Ophthalmol; 1968 Mar; 79(3):279-82. PubMed ID: 5694289
    [No Abstract]   [Full Text] [Related]  

  • 45. Methylprednisolone and Graves' ophthalmopathy.
    Dandona P; Havard CW; Mier A
    BMJ; 1989 Mar; 298(6676):830. PubMed ID: 2496877
    [No Abstract]   [Full Text] [Related]  

  • 46. [Treatment of the malignant phase of infiltrative-edematous exophthalmos in Graves-Basedow disease].
    Zgliczyński S; Górowski T; Jastrzebska H; Janik J; Machnicka J; Ulkowski M; Kuś J; Bonisławski D
    Pol Tyg Lek; 1984 Jul 16-23; 39(29-30):981-6. PubMed ID: 6548809
    [No Abstract]   [Full Text] [Related]  

  • 47. [Surgical treatment of Basedow's exophthalmos].
    Trepsat F; Durand L; Trepsat C; San Giuolo R
    Bull Soc Ophtalmol Fr; 1981 Nov; 81(11):987-91. PubMed ID: 6896170
    [No Abstract]   [Full Text] [Related]  

  • 48. [Paralysis of eye elevation of unknown cause simulating Basedow's paralysis].
    Hugonnier R; Magnard P; Noel G
    Bull Soc Ophtalmol Fr; 1968 Jan; 68(1):64-5. PubMed ID: 5755155
    [No Abstract]   [Full Text] [Related]  

  • 49. [Treatment of Basedow's exophthalmos].
    Mornex R
    Rev Prat; 1976 Dec; 26(55):3981-93. PubMed ID: 1036792
    [No Abstract]   [Full Text] [Related]  

  • 50. [Medical treatment of dysthyroid orbitopathy].
    Badelon I; Morax S
    J Fr Ophtalmol; 2004 Sep; 27(7):822-4. PubMed ID: 15499285
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Motion characteristics of the eye in the Basedow's disease patient.
    Sato M; Saito S
    Fukushima J Med Sci; 1974 Mar; 20(1-2):71-80. PubMed ID: 4480370
    [No Abstract]   [Full Text] [Related]  

  • 52. [Studies of the action of prenylamine in Basedow's disease before, during and after treatment with iodine-131].
    Riviere J; Latapie JL; Roger P; Blein JP
    Rev Fr Endocrinol Clin; 1969; 10(5):Suppl:1-4. PubMed ID: 5395882
    [No Abstract]   [Full Text] [Related]  

  • 53. [Value of Lithium carbonate in the treatment of the initial phase of Basedow's disease].
    Charpentier G; Aubry P; Coutris G; Thomas M
    Agressologie; 1982 Feb; 23(B):95-7. PubMed ID: 6805351
    [No Abstract]   [Full Text] [Related]  

  • 54. [Treatment of malignant exophthalmos with immunosuppressive agents].
    Simonin ; Saracco ; L'Epine-Bouyrie ; Vola
    Bull Soc Ophtalmol Fr; 1969 Feb; 69(2):211-3. PubMed ID: 5408908
    [No Abstract]   [Full Text] [Related]  

  • 55. [Effect of guanethidine eyedrops on the ocular manifestations of Basedow's disease].
    Berkman N; Joseph E
    Arch Ophtalmol Rev Gen Ophtalmol; 1971; 31(8):617-28. PubMed ID: 4256931
    [No Abstract]   [Full Text] [Related]  

  • 56. [On various circumstances aggravating the development of Basedow's disease].
    Latapie M
    J Med Bord; 1967 May; 144(5):729-32. PubMed ID: 5633082
    [No Abstract]   [Full Text] [Related]  

  • 57. [Ocular manifestations of Basedow's disease and local administration of guanethidine].
    Berkman N; Joseph E
    Presse Med (1893); 1971 Jan; 79(3):83-6. PubMed ID: 5107433
    [No Abstract]   [Full Text] [Related]  

  • 58. [Results of treatment of malignant exophthalmos by intrasellar implantation of yttrium 90].
    Molinatti GM
    Acta Isot (Padova); 1964 Dec; 4(4):399-416. PubMed ID: 5898108
    [No Abstract]   [Full Text] [Related]  

  • 59. [Treatment of severe endocrine ophthalmopathy with cyclosporin A].
    Bakó G; Fórizs E; Herczeg L; Kolozsvári L; Leövey A
    Orv Hetil; 1987 Aug; 128(35):1843-4. PubMed ID: 3627788
    [No Abstract]   [Full Text] [Related]  

  • 60. [Successful treatment by plasmapheresis of progressive edematous-infiltrative ophthalmopathy after corticotherapy failure].
    Pilarska K; Syrenicz A
    Pol Tyg Lek; 1987 Sep; 42(39):1230-1. PubMed ID: 3325947
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.